 |
|
Long-term Outcomes of Initial Antidepressant Drug Choice in a "Real World" Randomized Trial
Gregory E. Simon, MD, MPH;
John Heiligenstein, MD;
Dennis Revicki, PhD;
Michael VonKorff, ScD;
Wayne J. Katon, MD;
Evette Ludman, PhD;
Louis Grothaus, MA;
Edward Wagner, MD, MPH
Arch Fam Med. 1999;8:319-325.
Objective To compare the long-term clinical, quality-of-life, and economic outcomes after an initial prescription for fluoxetine, imipramine hydrochloride, or desipramine hydrochloride.
Design Randomized, controlled trial.
Setting Primary care clinics of a staff-model health maintenance organization in the Seattle, Wash, area.
Patients Four hundred seventy-one adults beginning antidepressant drug treatment for depression.
Intervention Random assignment of initial medication (desipramine, fluoxetine, or imipramine), with treatment (dosing, medication changes or discontinuation, and follow-up visits) managed by a primary care physician.
Measurements Interviews at baseline and at 6, 9, 12, 18, and 24 months examined medication use, clinical outcomes (Hamilton Depression Rating Scale and depression subscale of the Hopkins Symptom Checklist), and quality of life (Medical Outcomes Study SF-36 Health Survey). Medical costs were assessed using the health maintenance organization's accounting data.
Results Patients assigned to fluoxetine therapy were significantly more likely to continue taking the initial antidepressant but no more likely to continue any antidepressant therapy. The fluoxetine group did not differ significantly from either tricyclic drug group on any measure of depression severity or quality of life. For 24 months, antidepressant drug costs were approximately $250 higher for patients assigned to fluoxetine therapy, but total medical costs were essentially identical.
Conclusions Initial selection of fluoxetine or a tricyclic antidepressant drug should lead to similar clinical outcomes, functional outcomes, and overall costs. Differences in antidepressant prescription costs are blunted by the large minority of tricyclic-treated patients who switch to use of more expensive medications. Restrictions on first-line use of fluoxetine in primary care will probably not reduce overall treatment costs.
From the Center for Health Studies, Group Health Cooperative (Drs Simon, VonKorff, Ludman, and Wagner and Mr Grothaus), and the Department of Psychiatry and Behavioral Sciences, University of Washington (Drs Simon and Katon), Seattle, Wash; Lilly Research Laboratories, Indianapolis, Ind (Dr Heiligenstein); and MEDTAP International, Bethesda, Md (Dr Revicki).
RELATED ARTICLES
The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 1999;8(4):291-293.
FULL TEXT
TCAs vs SSRIs: Same Bang for Whose Buck?
Joseph J. Gallo
Arch Fam Med. 1999;8(4):326-327.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Antidepressant Switching Among Adherent Patients Treated for Depression
Marcus et al.
Psychiatr. Serv. 2009;60:617-623.
ABSTRACT
| FULL TEXT
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT
Implications of part d for mentally ill dual eligibles: a challenge for medicare.
Morden and Garrison
Health Aff (Millwood) 2006;25:491-500.
ABSTRACT
| FULL TEXT
Continuity of Antidepressant Treatment for Adults With Depression in the United States
Olfson et al.
Am. J. Psychiatry 2006;163:101-108.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Evidence-Based Pharmacotherapy or Cognitive Behavior Therapy Compared With Community Referral for Major Depression in Predominantly Low-Income Minority Women
Revicki et al.
Arch Gen Psychiatry 2005;62:868-875.
ABSTRACT
| FULL TEXT
Change in Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder Treated With Fluoxetine: A Placebo-Controlled Study
Phillips and Rasmussen
Psychosomatics 2004;45:438-444.
ABSTRACT
| FULL TEXT
Quantitative analysis of sponsorship bias in economic studies of antidepressants
Baker et al.
Br. J. Psychiatry 2003;183:498-506.
ABSTRACT
| FULL TEXT
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
Charlier et al.
J Psychopharmacol 2002;16:369-372.
ABSTRACT
Two-Year Effects of Quality Improvement Programs on Medication Management for Depression
Unutzer et al.
Arch Gen Psychiatry 2001;58:935-942.
ABSTRACT
| FULL TEXT
Antidepressant selection and economic outcome: a review of methods and studies from clinical practice
CROWN
Br. J. Psychiatry 2001;179
:s18-s22.
ABSTRACT
| FULL TEXT
Amitriptyline: still efficacious, but at what cost?
THOMPSON
Br. J. Psychiatry 2001;178:99-100.
FULL TEXT
The Electronic Medical Record: A Randomized Trial of Its Impact on Primary Care Physicians' Initial Management of Major Depression
Rollman et al.
Arch Intern Med 2001;161:189-197.
ABSTRACT
| FULL TEXT
Managing Depression in Medical Outpatients
Whooley and Simon
NEJM 2000;343:1942-1950.
FULL TEXT
More people with depression continued treatment with fluoxetine than with desipramine or imipramine
Anderson
Evid. Based Med. 2000;5:51-51.
FULL TEXT
More people with depression continued treatment with fluoxetine than with desipramine or imipramine
Anderson
Evid. Based Ment. Health 2000;3:23-23.
FULL TEXT
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2000;14:3-20.
ABSTRACT
TCAs vs SSRIs: Same Bang for Whose Buck?
Gallo
Arch Fam Med 1999;8:326-327.
FULL TEXT
|
